Sanofi grabs Chinese rights to Arrowhead rare disease drug

Sanofi grabs Chinese rights to Arrowhead rare disease drug

Sanofi has paid $130 million upfront for Chinese rights to an Arrowhead Pharma drug for rare disease familial chylomicronaemia syndrome.

Sanofi Secures Exclusive Rights to Develop and Commercialize Plozasiran in China for Hypertriglyceridemia

Arrowhead Pharmaceuticals has announced that its subsid […] The post Sanofi Secures Exclusive Rights to Develop and Commercialize Plozasiran in China for Hypertriglyceridemia first appeared on GeneOnline News. The post Sanofi Secures Exclusive Rights to Develop and Commercialize Plozasiran in China for Hypertriglyceridemia appeared first on GeneOnline News.

Arrowhead sells hypertriglyceridemia candidate rights in China

Arrowhead's subsidiary Visirna has entered an agreement with Sanofi for plozasiran, a potential treatment for hypertriglyceridemia.